Sildenafil: A new oral therapy for erectile dysfunction

Mark Bradley Noss, George J. Christ, Arnold Melman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Sildenafil citrate (Viagra®) is a relatively selective 5- phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which is turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t 1/2 of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalDrugs of Today
Volume35
Issue number3
StatePublished - Mar 1999

Fingerprint

Erectile Dysfunction
Penile Erection
Phosphodiesterase 5 Inhibitors
Muscle Relaxation
Guanylate Cyclase
Therapeutics
Heme
Smooth Muscle
Oral Administration
Sildenafil Citrate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Noss, M. B., Christ, G. J., & Melman, A. (1999). Sildenafil: A new oral therapy for erectile dysfunction. Drugs of Today, 35(3), 211-217.

Sildenafil : A new oral therapy for erectile dysfunction. / Noss, Mark Bradley; Christ, George J.; Melman, Arnold.

In: Drugs of Today, Vol. 35, No. 3, 03.1999, p. 211-217.

Research output: Contribution to journalArticle

Noss, MB, Christ, GJ & Melman, A 1999, 'Sildenafil: A new oral therapy for erectile dysfunction', Drugs of Today, vol. 35, no. 3, pp. 211-217.
Noss MB, Christ GJ, Melman A. Sildenafil: A new oral therapy for erectile dysfunction. Drugs of Today. 1999 Mar;35(3):211-217.
Noss, Mark Bradley ; Christ, George J. ; Melman, Arnold. / Sildenafil : A new oral therapy for erectile dysfunction. In: Drugs of Today. 1999 ; Vol. 35, No. 3. pp. 211-217.
@article{381df2c84c6342818a2a7738395c9573,
title = "Sildenafil: A new oral therapy for erectile dysfunction",
abstract = "Sildenafil citrate (Viagra{\circledR}) is a relatively selective 5- phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which is turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t 1/2 of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.",
author = "Noss, {Mark Bradley} and Christ, {George J.} and Arnold Melman",
year = "1999",
month = "3",
language = "English (US)",
volume = "35",
pages = "211--217",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - Sildenafil

T2 - A new oral therapy for erectile dysfunction

AU - Noss, Mark Bradley

AU - Christ, George J.

AU - Melman, Arnold

PY - 1999/3

Y1 - 1999/3

N2 - Sildenafil citrate (Viagra®) is a relatively selective 5- phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which is turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t 1/2 of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.

AB - Sildenafil citrate (Viagra®) is a relatively selective 5- phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which is turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t 1/2 of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0032935216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032935216&partnerID=8YFLogxK

M3 - Article

C2 - 12973386

AN - SCOPUS:0032935216

VL - 35

SP - 211

EP - 217

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 3

ER -